PTC Therapeutics (PTCT) Tops Q2 EPS by 6c

PTC Therapeutics (NASDAQ: PTCT) reported Q2 EPS of ($1.14), $0.06 better than the analyst estimate of ($1.20). Revenue for the quarter came in at $6.77 million versus the consensus estimate of $7.74 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.

You May Also Be Interested In

• Meritage Homes Corporation (MTH) Tops Q1 EPS by 151c; offers guidance
• Newmarket (NEU) Reports Q1 EPS of $11.23
• ESSA Bancorp (ESSA) Tops Q2 EPS by 13c